Literature DB >> 15276147

Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy.

N F Moran1, K Poole, G Bell, J Solomon, S Kendall, M McCarthy, D McCormick, L Nashef, J Sander, S D Shorvon.   

Abstract

OBJECTIVES: To describe the clinical characteristics of epilepsy in a representative sample of the UK population, including seizure frequency and severity; overall severity of epilepsy; patterns of anti-epileptic drug (AED) use; and the impact of epilepsy on patients' lives. Secondly, to determine if these characteristics differ according to age.
METHOD: A large, geographically comprehensive survey of people with epilepsy by means of a postal questionnaire distributed by general practitioners to 3455 unselected patients receiving AEDs for epilepsy, regardless of age or type of epilepsy and including all regions of the UK. Data were collected on age and gender; age of onset of seizures; seizure frequency and severity; AED use and adverse effect levels; and impact on life of epilepsy. Sub-analyses were performed with stratification by epilepsy severity and age-group.
RESULTS: There were 1652 completed replies. The mean age was 44.2 years; there were 47.2% males, 48.5% females (4.4% not recorded). The mean age at first seizure, 25.1 years, and the mean duration of epilepsy, 19.7 years, were comparable with previous studies. In the preceding one year, 51.7% of patients had no seizures; 7.9% one seizure, 17.2% 2-9 seizures and 23.2% 10 or more. Sixty-four percent of patients had epilepsy classified as mild and 32% severe. There was a marked and significant decrement of seizure frequency with increasing age. The most commonly used AEDs were carbamazepine (37.4%), valproate (35.7%), phenytoin (29.4%), phenobarbitone or primidone (14.2%) and lamotrigine (10.3%). Monotherapy was used in 68% of patients. Patients taking multiple AEDs reported significantly higher levels of adverse effects and worse seizure control. The major impacts of epilepsy on life were work and school difficulties, driving prohibition, psychological and social life. The impacts listed varied with the epilepsy severity and age.
CONCLUSIONS: Seizures remain uncontrolled in up to half of all people with epilepsy in the UK with significant impact on work, family and social life. Previously, there has been a deficiency of data on the characteristics of epilepsy in older people, although it is recognized that the condition is of increasing epidemiological importance in this age group. We have found clear differences in the clinical characteristics of epilepsy in older people, particularly that seizure frequency appears to decline with increasing age. Copyright 2003 BEA Treading Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276147     DOI: 10.1016/j.seizure.2003.10.002

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  30 in total

Review 1.  Valproic acid in epilepsy : pregnancy-related issues.

Authors:  Pierre Genton; Franck Semah; Eugen Trinka
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Molecular mechanisms of epilepsy.

Authors:  Kevin Staley
Journal:  Nat Neurosci       Date:  2015-02-24       Impact factor: 24.884

3.  Knowledge translation of an online tool to determine candidacy for epilepsy surgery evaluation.

Authors:  Khara M Sauro; Jayna Holroyd-Leduc; Samuel Wiebe; Hude Quan; Lara Cooke; J Helen Cross; Gary W Mathern; Heather Armson; Julie Stromer; Nathalie Jetté
Journal:  Neurol Clin Pract       Date:  2016-08

4.  EEG CLassification Via Convolutional Neural Network-Based Interictal Epileptiform Event Detection.

Authors:  John Thomas; Luca Comoretto; Jing Jin; Justin Dauwels; Sydney S Cash; M Brandon Westover
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2018-07

5.  National Audit of Seizure management in Hospitals (NASH): results of the national audit of adult epilepsy in the UK.

Authors:  Peter A Dixon; Jamie J Kirkham; Anthony G Marson; Mike G Pearson
Journal:  BMJ Open       Date:  2015-03-31       Impact factor: 2.692

6.  Self-management education for adults with poorly controlled epilepsy (SMILE (UK)): statistical, economic and qualitative analysis plan for a randomised controlled trial.

Authors:  Nicholas Magill; Leone Ridsdale; Laura H Goldstein; Paul McCrone; Myfanwy Morgan; Adam J Noble; Gus Baker; Mark Richardson; Stephanie Taylor; Sabine Landau
Journal:  Trials       Date:  2015-06-12       Impact factor: 2.279

Review 7.  Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review.

Authors:  Sophia Yui Kau Fong; Qiong Gao; Zhong Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629

8.  Seizing an opportunity: broader definitions of epilepsy may lead to better treatments.

Authors:  Helen E Scharfman
Journal:  Cerebrum       Date:  2010-09-22

9.  Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study.

Authors:  Alex Dregan; Judith Charlton; Charles D A Wolfe; Martin C Gulliford; Hugh S Markus
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-06-02       Impact factor: 2.890

10.  Self-Management education for adults with poorly controlled epILEpsy (SMILE (UK)): a randomised controlled trial protocol.

Authors:  Ines Kralj-Hans; Laura H Goldstein; Adam J Noble; Sabine Landau; Nicholas Magill; Paul McCrone; Gus Baker; Myfanwy Morgan; Mark Richardson; Stephanie Taylor; Leone Ridsdale
Journal:  BMC Neurol       Date:  2014-04-03       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.